Physician profile
Olivia Guzman
NPI 1326275587
$4,124.91
in general payments reported to CMS, 2019-2025
30 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $851 · 2022: $739 · 2023: $895 · 2024: $1,168 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,030.04 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $546.64 | 2021-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $349.25 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $337.14 | 2021-2024 | |
| Abbvie INC. | $313.42 | 2021-2025 | |
| Philips North America LLC | $217.02 | 2023-2024 | (5050) Ext Holter, (5044) Mcot |
| Glaxosmithkline, LLC. | $151.01 | 2023-2025 | Arexvy, Shingrix |
| Viiv Healthcare Company | $130.02 | 2024-2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $111.29 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $107.18 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $87.36 | 2023 | Quviviq |
| Alkermes, INC. | $70.48 | 2021-2024 | Vivitrol, Vivitrol |
| Janssen Pharmaceuticals, INC | $70.09 | 2021 | |
| Organon LLC | $69.70 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $67.37 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $58.86 | 2021 | |
| Mylan Specialty L.P. | $50.54 | 2021-2022 | |
| Edwards Lifesciences Corporation | $42.85 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals Lp | $42.84 | 2023-2024 | Farxiga, Airsupra |
| Lundbeck LLC | $35.44 | 2024 | Rexulti |
| Dexcom, INC. | $34.74 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $30.59 | 2021 | |
| Harmony Biosciences LLC | $29.91 | 2023 | Wakix |
| Seqirus USA INC | $29.48 | 2022 | |
| Hologic Sales and Service, LLC | $25.14 | 2025 | Aptima |
| Sanofi Pasteur INC. | $18.69 | 2022 | |
| Gilead Sciences, INC. | $18.65 | 2021 | |
| Levita Magnetics International Corp. | $18.08 | 2024 | Toothed Grasper, Magnetic Surgical System |
| Exact Sciences Corporation | $16.15 | 2025 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.